Cardiff Oncology

Cardiff Oncology

CRDF· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -35.3% in FY2025

Mark Erlander is the CEO of Cardiff Oncology and was paid $3.0M in FY2025 (Dec), up 26%.

Pay$100 in the stock at the end of FY21 → $47
CEO pay is from each Cardiff Oncology proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Mark ErlanderFY2025
  2. 2Roger Sidhu, CMOFY2025
  3. 3James LevineFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Cardiff Oncology paid its 3 named executives $6.8M in total in FY2025 (Dec). CEO Mark Erlander was paid $3.0M of that.

Name
Mark ErlanderCEO
Roger Sidhu, CMONot disclosedNot disclosed
James LevineCFO

of each named executive, from the Summary Compensation Table of each proxy.

Peers20

See all

The FY2025 (Dec) proxy of Cardiff Oncology names 20 peer companies for pay. Pay versus performance data of Cardiff Oncology for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board3

See all
  • Dr. Rodney S. MarkinChair · 11 yr on the boardIndependentAudit, Compensation—Paid as an executive
  • Dr. James O. ArmitageDirector · 5 yr on the boardIndependentAudit, Nominating—Paid as an executive
  • Lâle WhiteDirector · 5 yr on the boardIndependentAudit (Chair), Compensation—Paid as an executive

The board of the latest proxy (FY2025).

Activity

Filings6

See all
Proxy statementDEF 14AApr 23, 2026FY2025
Annual report10-KFeb 24, 2026FY2025
Proxy statementDEF 14AApr 29, 2025FY2024
Annual report10-KFeb 27, 2025FY2024
Proxy statementDEF 14AApr 25, 2024FY2023
Annual report10-KFeb 29, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data